Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below....
On March 9, AroCell, Anders Hultman CEO, presented the latest developments and the future of the company at the Stockholm Corporate Finance Life Science Capital Markets Days at the IVA conference center in Stockholm. Stockholm Corporate Finance arranged the capital...
This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
(In Swedish)
IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms, said Gunnar Wahlberg, CEO of IDL...
In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer. Read the article here (Swedish)
Quantification of Thymidine Kinase 1 in serum with AroCell TK 210 ELISA is now validated for use on an open automation platform for ELISA. This enhances the application and use of the assay. We have now validated AroCell TK 210 ELISA for use on an automation platform,...
A new Redeye interview with Michael Brobjer, AroCell CEO, commenting interim report for the second quarter of 2020. See the interview on Redeye's website.
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF. Read the press release here
